Geron Corporation
GERN · Nasdaq · United States
Share price · GERN
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when GERN's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 4 Nov 2026+16.1%
- 28 Oct 2026-15.8%
- 11 Aug 2026+10.1%
Nothing announced by GERN that day or the session before.
- 7 Aug 2026-5.7%
- 5 Aug 2026+21.6%
- 30 Jul 2026-4.3%
Nothing announced by GERN that day or the session before.
- 6 Jul 2026+5.9%
Nothing announced by GERN that day or the session before.
- 1 Apr 2026+11.4%
Nothing announced by GERN that day or the session before.
- 25 Feb 2026-11.8%
- 24 Feb 2026+10.2%
Share of unusual movement by asset
For each asset, the share of GERN's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
Imetelstat(Rytelo) | Approved | TelomeraseRNA / oligonucleotide | Myelodysplastic Syndromes |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2028 (1)
June 2028 (1)
What to watch
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $60M | $13M | $69M+ $217M short-term inv. | —$10M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $57M | $22M | $63M+ $238M short-term inv. | $17M-$16M operating cash flow | report ↗ |
| 2026-Q1 | $52M | $15M | $69M+ $244M short-term inv. | $3.6M-$63M operating cash flow | report ↗ |
| 2025-Q3 | $47M | $21M | $78M+ $302M short-term inv. | $18M-$14M operating cash flow | report ↗ |
| 2025-Q2 | $49M | $22M | $78M+ $310M short-term inv. | $16M-$27M operating cash flow | report ↗ |
| 2025-Q1 | $40M | $15M | $84M+ $313M short-term inv. | $20M-$48M operating cash flow | report ↗ |
| 2024-Q3 | $28M | $20M | $60M+ $279M short-term inv. | $26M-$59M operating cash flow | report ↗ |
| 2024-Q2 | $0.9M | $31M | $117M+ $246M short-term inv. | $67M-$53M operating cash flow | report ↗ |
| 2024-Q1 | $0.3M | $29M | $190M+ $253M short-term inv. | $55M-$62M operating cash flow | report ↗ |
| 2023-Q3 | $0.2M | $29M | $31M+ $283M short-term inv. | $45M-$51M operating cash flow | report ↗ |
| 2023-Q2 | <$0.1M | $35M | $57M+ $314M short-term inv. | $49M-$30M operating cash flow | report ↗ |
| 2023-Q1 | <$0.1M | $27M | $113M+ $268M short-term inv. | $38M-$46M operating cash flow | report ↗ |
| 2022-Q3 | $0.3M | $25M | $61M+ $134M short-term inv. | $41M-$30M operating cash flow | report ↗ |
| 2022-Q2 | $0.1M | $21M | $76M+ $143M short-term inv. | $28M-$29M operating cash flow | report ↗ |
| 2022-Q1 | $0.1M | $22M | $31M+ $135M short-term inv. | $30M-$34M operating cash flow | report ↗ |
| 2021-Q3 | $0.1M | $19M | $29M+ $147M short-term inv. | $27M-$23M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $71M | $78M+ $280M short-term inv. | $21M-$111M operating cash flow | report ↗ |
Geron reported full-year 2025 product revenue net of $183.6M and total revenues of $183.9M, compared with $76.5M and $77.0M in 2024. R&D expenses were $73.7M (R&D spend was listed at $71.43M, down 31.1% YoY). Year-end cash, cash equivalents, restricted cash and marketable securities were approximately $401.1M, and the full-year net loss was $85.8M with quarterly net burn of $83.5M.
For 2026, Geron guided RYTELO net product revenue to $220M-$240M and total operating expenses to $230M-$240M. The company highlighted a 9% sequential Q4 increase in RYTELO demand, about 1,300 ordering accounts, new medical publications, and ASH 2025 data, along with a December 2025 workforce reduction of approximately one-third and $17.0M in restructuring charges. Pipeline catalysts include the IMpactMF interim analysis in relapsed/refractory myelofibrosis and initial real-world evidence data in LR-MDS, both expected in the second half of 2026.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | — | $104M | $79M+ $328M short-term inv. | $44M-$219M operating cash flow | report ↗ |
| 2023-FY | $0.2M | $125M | $70M+ $264M short-term inv. | $46M-$168M operating cash flow | report ↗ |
| 2022-FY | $0.6M | $96M | $57M+ $116M short-term inv. | $35M-$127M operating cash flow | report ↗ |
| 2021-FY | $1.4M | $86M | $35M+ $149M short-term inv. | $29M-$96M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 2 purchases ($62K), 1 sale ($19K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-16 | Williams Timothy · EVP and Chief Legal Officer | Open-market purchase | 12,000 | $0.94 | $11K | Form 4 |
| 2026-11-13 | Semerjian Harout · director, President & CEO | Open-market purchase | 53,500 | $0.95 | $51K | Form 4 |
| 2026-09-30 | Spiegel Robert J. · director | Award / grant | 6,351 | $1.23 | $8K | Form 4 |
| 2026-06-30 | Spiegel Robert J. · director | Award / grant | 6,103 | $1.28 | $8K | Form 4 |
| 2026-05-20 | Bir Dawn Carter · director | Award / grant (derivative) | 220,000 | — | — | Form 4 |
| 2026-05-20 | McDonald John F · director | Award / grant (derivative) | 220,000 | — | — | Form 4 |
| 2026-05-20 | Molineaux Susan · director | Award / grant (derivative) | 220,000 | — | — | Form 4 |
| 2026-05-20 | O'Farrell Elizabeth G. · director | Award / grant (derivative) | 220,000 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 255 reporting institutions held 497.2M shares ($737.1M, 77.2% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | RA CAPITAL MANAGEMENT, L.P. | 63,771,366 | $95.0M |
| 2 | BlackRock, Inc. | 47,319,779 | $70.5M |
| 3 | Soleus Capital Management, L.P. | 41,508,659 | $61.8M |
| 4 | Deep Track Capital, LP | 31,720,278 | $47.3M |
| 5 | STATE STREET CORP | 30,497,183 | $45.4M |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 26,669,029 | $39.7M |
| 7 | CITADEL ADVISORS LLC | 21,576,569 | $32.1M |
| 8 | Point72 Asset Management, L.P. | 20,457,134 | $30.5M |
| 9 | Clearbridge Investments, LLC | 19,620,320 | $29.2M |
| 10 | Eversept Partners, LP | 18,834,883 | $28.1M |
| 11 | GEODE CAPITAL MANAGEMENT, LLC | 13,670,785 | $20.4M |
| 12 | MORGAN STANLEY | 12,665,119 | $18.9M |
| 13 | Nantahala Capital Management, LLC | 11,225,000 | $16.7M |
| 14 | GOLDMAN SACHS GROUP INC | 11,176,591 | $16.7M |
| 15 | Vivo Capital, LLC | 8,671,797 | $12.9M |